Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-12-13
2003-01-07
Kunz, Gary L. (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S320100, C435S325000, C435S069100
Reexamination Certificate
active
06504023
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates generally to cytokine receptors, and more specifically, to Type II (B Cell) Interleukin-1 receptors.
Interleukin-1&agr; (IL-1&agr;) and Interleukin-1&bgr; and (IL-1&bgr;) are distantly related polypeptide hormones which play a central role in the regulation of immune and inflammatory responses. These two proteins act on a variety of cell types and have multiple biological activities. The diversity of biological activity ascribed to IL-1&agr; and IL-1&bgr; is mediated by specific plasma membrane receptors which bind both IL-1&agr; and IL-1&bgr;. Due to the wide range of biological activities mediated by IL-1&agr; and IL-1&bgr; it was originally believed that the IL-1 receptors should be highly conserved in a variety of species and expressed on a large variety of cells.
Structural chracterization by ligand affinity cross-linking techniques has demonstrated that, despite their significant divergence in sequence, IL-1&agr; and IL-1&bgr; bind to the same cell surface receptor molecule on T cells and fibroblasts (Dower et al.,
Nature
(London) 324:266, 1986; Bird et al.,
Nature
(London) 324:263, 1986; Dower et al.,
Proc. Natl. Acad. Sci. USA
83:1060, 1986). The IL-1 receptor on murine and human T cells has been identified by cDNA expression cloning and N-terminal sequence analysis as an integral membrane glycoprotein that binds IL-1&agr; and IL-1&bgr; and has a molecular weight of 80,000 kDa (Sims et al.,
Science
241:585, 1988; Sims et al.,
Proc. Natl. Acad. Sci. USA
86:8946, 1989).
It is now clear, however, that this 80 kDa IL-1 receptor protein does not mediate all the diverse biological effects of IL-1. Subsequent affinity cross-linking studies indicate that IL-1 receptors on the Epstein Barr virus (EBV)-transformed human B cell lines VDS-O and 3B6, the EBV-positive Burkitt's lymphoma cell line Raji, and the murine pre-B cell line 70Z/3, have a molecular weight of 60,000 to 68,000 kDa (Matsushima et al.,
J. Immunol.
136:4496, 1986; Bensimon et al.,
J. Immunol.
142:2290, 1989; Bensimon et al.,
J. Immunol.
143:1168, 1989; Horuk et al.,
J. Biol. Chem.
262:16275, 1987; Chizzonite et al.,
Proc. Natl. Acad. Sci. USA
86:8029, 1989; Bomsztyk et al.,
Proc. Natl. Acad. Sci. USA
86:8034, 1989). Moreover, comparison of the biochemical properties and kinetic analysis of the IL-1 receptor in the Raji B cell line with EL-4 murine T lymphoma cell line showed that Raji cells had lower binding affinity but much higher receptor density per cell than a subclone of EL-4 T cells (Horuk et al.,
J. Biol. Chem.
262:16275, 1987). Raji cells also failed to internalize IL-1 and demonstrated altered receptor binding affinities with IL-1 analogs. (Horuk et al.,
J. Biol. Chem.
262:16275, 1987). These data suggest that the IL-1 receptors expressed on B cells (referred to herein as type II IL-1 receptors) are different from IL-1 receptors detected on T cells and other cell types (referred to herein as type I IL-1 receptors).
In order to study the structural and biological characteristics of type II IL-1R and the role played by type II IL-1R in the responses of various cell populations to IL-1 stimulation, or to use type II IL-1R effectively in therapy, diagnosis, or assay, homogeneous compositions are needed. Such compositions are theoretically available via purification of receptors expressed by cultured cells, or by cloning and expression of genes encoding the receptors. Prior to the present invention, however, several obstacles prevented these goals from being achieved.
First, no cell lines have previously been known to express high levels of type II IL-1R constitutively and continuously, and cell lines known to express type II IL-1R did so only in low numbers (500 to 2,000 receptors/cell) which impeded efforts to purify receptors in amounts sufficient for obtaining amino acid sequence information or generating monoclonal antibodies. The low numbers of receptors has also precluded any practical translation assay-based method of cloning.
Second, the significant differences in DNA sequence between type I IL-1R and type II IL-1R has precluded cross-hybridization using a murine type IL-1R cDNA (Bomsztyk et al.,
Proc. Natl. Acad. Sci. USA
86:8034, 1989, and Chizzonite et al.,
Proc. Natl. Acad. Sci. USA
86:8029, 1989).
Third, even if a protein composition of sufficient purity could be obtained to permit N-terminal protein sequencing, the degeneracy of the genetic code may not permit one to define a suitable probe without considerable additional experimentation. Many iterative attempts may be required to define a probe having the requisite specificity to identify a hybridizing sequence in a cDNA library. Although direct expression cloning techniques avoid the need for repetitive screening using different probes of unknown specificity and have been useful in cloning other receptors (e.g., type I IL-1R), they are not sufficiently sensitive to be suitable for using in identifying type II IL-1R clones from cDNA libraries derived from cells expressing low numbers of type II IL-1R.
Thus, efforts to purify the type II IL-1R or to clone or express genes encoding type II IL-1R have been significantly impeded by lack of purified receptor, a suitable source of receptor mRNA, and by a sufficiently sensitive cloning technique.
SUMMARY OF THE INVENTION
The present invention provides isolated type II IL-1R and isolated DNA sequences encoding type II IL-1R, in particular, human type II IL-1R, or analogs thereof. Preferably, such DNA sequences are selected from the group consisting of (a) cDNA clones having a nucleotide sequence derived from the coding region of a native type II IL-1R gene, such as clone 75; (b) DNA sequences capable of hybridization to the cDNA clones of (a) under moderately stringent conditions and which encode biologically active IL-1R molecules; and (c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which encode biologically active IL-1R molecules. The present invention also provides recombinant expression vectors comprising the DNA sequences defined above, recombinant type II IL-1R molecules produced using the recombinant expression vectors, and processes for producing the recombinant type II IL-1R molecules utilizing the expression vectors.
The present invention also provides substantially homogeneous protein compositions comprising type II IL-1R.
The present invention also provides compositions for use in therapy, diagnosis, assay of type II IL-1R, or in raising antibodies to type II IL-1R, comprising effective quantities of soluble native or recombinant receptor proteins prepared according to the foregoing processes.
These and other aspects of the present invention will become evident upon reference to the following detailed description.
REFERENCES:
patent: 5350683 (1994-09-01), Sims et al.
Bork, P. (1996), Go hunting in sequence databases but watch out for the traps. Trends Genetics, 12(10):425-427.*
Bork, P. (1998), Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Res., 10:398-400, esp. p. 400.*
Doerks, T. (1998), Protein annotation: detective work for function prediction., Trends Genetics. 14(6):248-250.*
Skolnick, J. (2000), From genes to protein structure and function: novel applications of computational approaches in the genomic era., trends Biotech., 18(1):34-39, esp. p. 36.*
Smith, T.F. and Zhang, X. (1997) The challenges of genome sequence annotation or “The devil is in the details”, Nature Biotechnology, 15:1222-1223.
Cosman David J.
Dower Steven K.
Lupton Stephen D.
Mosley Bruce A.
Sims John E.
Henry Janis C.
Immunex Corporation
Kunz Gary L.
Wegert Sandra
LandOfFree
DNA encoding type II IL-1 receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA encoding type II IL-1 receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding type II IL-1 receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3029320